血管紧张素-(1-7)与肿瘤

doi:10.3760/cma.j.issn.1673-422X.2015.04.009

摘要/Abstract

摘要： 血管紧张素-(1-7)［Ang-(1-7)］是近年来发现的肾素血管紧张素系统中一种内源性七肽，与血管紧张素转换酶2（ACE2）及Mas受体共同构成ACE2Ang(17)Mas轴，起到拮抗ACEAngⅡAngⅡ 1型受体轴的作用。近期发现除了其在心血管疾病中发挥作用外，在肿瘤的治疗中也有一定的作用，包括抑制血管生成、抗细胞增殖以及抑制肿瘤纤维化等。研究Ang(17)的作用及作用机制能够为肿瘤的治疗及预防提供新的研究方向。

关键词: 肿瘤, 血管紧张素-(1-7)

Abstract: Angiotensin-(1-7) ［Ang-(1-7)］ is an endogenous peptidehormone of the reninangiotensin system. Ang-(1-7), angiotensinconverting enzyme 2 (ACE2) and MAS receptor constitute ACE2Ang-(1-7)Mas axis, which antagonizes the ACEAngⅡAngⅡ type 1 receptor axis. Recent studies indicate that Ang-(1-7) has certain effects on treating tumors, including inhibition of angiogenesis, anticell proliferation and inhibition of tumor fibrosis. Researches on the roles and mechanisms of Ang-(1-7) can provide new target for treatment and prevention of cancer.

Key words: Neoplasms, Angiotensin-(1-7）

赵乐康, 于金明 . 血管紧张素-(1-7)与肿瘤[J]. 国际肿瘤学杂志, 2015, 42(4): 274-276.

ZHAO Le-Kang, YU Jin-Ming- . Angiotensin-(1-7) and tumors[J]. Journal of International Oncology, 2015, 42(4): 274-276.

参考文献

［1］ Ferrario CM, Chappell MC, Tallant EA, et al. Counterregulatory actions of angiotensin(17)［J］. Hypertension, 1997, 30(3): 535541. ［2］ Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin(17) in vascular smooth muscle［J］. Hypertension, 1999, 34(2): 950957. ［3］ Santos RA, CampagnoleSantos MJ, Andrade SP. Angiotensin(17): an update［J］. Regul Pept, 2000, 91(13): 4562. ［4］ Welches WR, Santos RA, Chappell MC, et al. Evidence that prolyl endopeptidase participates in the processing of brain angiotensin［J］. J Hypertens, 1991, 9(7): 631638. ［5］ Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase［J］. Life Sci, 1993, 52(18): 14611480. ［6］ Ferrario CM, Iyer SN. Angiotensin(17): a bioactive fragment of the reninangiotensin system［J］. Regul Pept, 1998, 78(13): 1318. ［7］ Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensinconverting enzyme(ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism［J］. Biochem J, 2004, 383(Pt 1): 4551. ［8］ Chappell MC, Pirro NT, Sykes A, et al. Metabolism of angiotensin(17) by angiotensinconvertingenzyme［J］. Hypertension, 1998, 31(2): 362367. ［9］ Iwata M, Cowling RT, Yeo SJ, et al. Targeting the ACE2Ang(17) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure［J］. J Mol Cell Cardiol, 2011, 51(4): 542547. ［10］ Tikellis C, Bernardi S, Burns WC. Angiotensinconverting enzyme 2 is a key modulator of the reninangiotensin system in cardiovascular and renal disease［J］. Curr Opin Nephrol Hypertens, 2011, 20(1): 6268. ［11］ CastroChaves P, Cerqueira R, Pintalhao M, et al. New pathways of the reninangiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy［J］. Expert Opin Ther Targets, 2010, 14(5): 485496. ［12］ Giani JF, Mayer MA, Muoz MC, et al. Chronic infusion of angiotensin(17) improves insulin resistance and hypertension induced by a highfructose diet in rats［J］. Am J Physiol Endocrinol Metab, 2009, 296(2): E262E271. ［13］ Liu C, Lv XH, Li HX, et al. Angiotensin(17) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes［J］. Acta Diabetol, 2012, 49(4): 291299. ［14］ Feng Y, Xia H, Cai Y, et al. Brainselective overexpression of human angiotensinconverting enzyme type 2 attenuates neurogenic hypertension［J］. Circ Res, 2010, 106(2): 373382. ［15］ Jiang T, Gao L, Guo J, et al. Suppressing inflammation by inhibiting NFκB pathway contributes to the neuroprotection of angiotensin(17) in rats with permanent cerebral ischemia［J］. Br J Pharmacol, 2012, 167(7): 15201532. ［16］ Leal MC, Pinheiro SV, Ferreira AJ, et al. The role of angiotensin(17) receptor Mas in spermatogenesis in mice and rats［J］. J Anat, 2009, 214(5): 736743. ［17］ Pringle KG, Tadros MA, Callister RJ, et al.The expression and localization of the human placental prorenin/reninangiotensin system throughout pregnancy: roles in trophoblast invasion and angiogenesis?［J］. Placenta, 2011, 32(12): 956962. ［18］ Costa AP, FagundesMoura CR, Pereira VM, et al. Angiotensin(17): a novel peptide in the ovary［J］. Endocrinology, 2003, 144(5):19421948. ［19］ Gallagher PE, Tallant EA. Inhibition of lung cancer cell growth by angiotensin(17)［J］. Carcinogenesis, 2004, 25(11): 20452052. ［20］ Cook KL, MethenyBarlow LJ, Tallant EA, et al. Angiotensin(17) reduces fibrosis in orthotopic breast tumors［J］. Cancer Res, 2010, 70(21): 83198328. ［21］ Krishnan B, Smith TL, Dubey P, et al. Angiotensin(17) attenuates metastatic prostate cancer and reduces osteoclastogenesis［J］. Prostate, 2013, 73(1): 7182. ［22］ SotoPantoja DR, Menon J, Gallagher PE, et al. Angiotensin(17) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor［J］. Mol Cancer Ther, 2009, 8(6): 16761683. ［23］ Menon J, SotoPantoja DR, Callahan MF,et al. Angiotensin(17) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase2［J］. Cancer Res, 2007, 67(6): 28092015. ［24］ Ni L, Feng Y, Wan H, et al. Angiotensin(17) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways［J］. Oncol Rep, 2012, 27(3):783790. ［25］ Gately S, Li WW. Multiple roles of COX2 in tumor angiogenesis: a target for antiangiogenic therapy［J］. Semin Oncol, 2004, 31(2):211. ［26］ Iniguez MA, Rodriguez A, Volpert OV, et al. Cyclooxygenase2: a therapeutic target in angiogenesis［J］. Trends Mol Med, 2003, 9(2): 7378. ［27］ Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence［J］. Breast Cancer Res, 2008, 10(1): 201. ［28］ Sheffer Y, Leon O, Pinthus JH, et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapymediated antitumoral effect［J］. Mol Cancer Ther, 2007, 6(2): 570577. ［29］ Kalluri R, Zeisberg M. Fibroblasts in cancer［J］. Nat Rev Cancer, 2006, 6(5): 392401. ［30］ De Wever O, Demetter P, Mareel M, et al. Stromal myofibroblasts are drivers of invasive cancer growth［J］. Int J Cancer, 2008, 123(10): 22292238. ［31］ Guise T. Examining the metastatic niche: targeting the microenvironment［J］. Semin Oncol, 2010, 37 Suppl 2: S214. ［32］ Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Srcdependent survival signals［J］. Cancer Cell, 2009, 16(7): 6778. ［33］ Gallagher PE, Tallant EA. Inhibition of human lung cancer cell growth by angiotensin(17)［J］. Carcinogenesis, 2004, 25(11): 20452052.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.